MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.345
+0.475
+16.55%
After Hours: 3.100 -0.245 -7.32% 19:59 05/07 EDT
OPEN
3.054
PREV CLOSE
2.870
HIGH
4.340
LOW
3.010
VOLUME
38.85M
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
0.7255
MARKET CAP
43.05M
P/E (TTM)
-2.2361
1D
5D
1M
3M
1Y
5Y
Auris Medical Stock Is Trading Higher As Bentrio Hit Primary Endpoint Goal In Allergic Rhinitis Study
Benzinga · 1d ago
Regional Health Properties, Auris Medical leads healthcare gainers; ChemoCentryx, Orphazyme among major losers
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aurinia Pharmaceuticals (AUPH) ...
Seekingalpha · 1d ago
Thinking about buying stock in Acasti Pharma, Ocugen, Castor Maritime, Naked Brand, or Auris Medical?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACST, OCGN, CTRM, NAKD, and EARS.
PR Newswire - PRF · 1d ago
Auris Medical Provides Update on Bentrio Program in Allergy
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians Pre-submission meeting with FDA supports 510(k) regulat...
GlobeNewswire · 1d ago
Auris Medical Says Meets Primary Efficacy Endpoint In Clinical Evaluation In Allergic Rhinitis
Auris Medical Provides Update on Bentrio Program in Allergy BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitis Clinically relevant and significant reduction in nasal
Benzinga · 1d ago
Vertigo Drugs Market to Register Incremental Revenue Opportunities During the Forecast Period 2021-2027
May 05, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Cosmetic Skin Care Market Size, By Product (Moisturizers,...
Heraldkeepers · 3d ago
OCGN, RRD, ERII and GOGL among premarket gainers
Alterity Therapeutics (ATHE) +22%.Welbilt (WBT) +19% on being acquired by The Middleby Corp.Sierra Metals (SMTS) +12%.Williams Industrial Services (WLMS) +12%.Uxin Limited (UXIN) +9%.inTEST Corporation (INTT) +8%.Ocugen (OCGN) +7%.Energy Recover (ERII) +7%...
Seekingalpha · 04/21 12:15
Vertigo Drugs Market Research Report by Type, by Distribution Channel – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 16, 2021 (Heraldkeepers) -- Global vertigo drugs market is segregated on the basis of product as, antihistamines, phenothiazines, and benzodiazepines....
Heraldkeepers · 04/16 11:13
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EARS. Analyze the recent business situations of Auris Medical Holding Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EARS stock price target is 15.19 with a high estimate of 15.19 and a low estimate of 15.19.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 1.12M
% Owned: 8.71%
Shares Outstanding: 12.87M
TypeInstitutionsShares
Increased
1
1.55K
New
7
183.41K
Decreased
1
76
Sold Out
3
36.87K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Meyer
Non-Executive Vice Chairman
James Healy
Chief Financial Officer/Primary Contact
Hernan Levett
General Counsel
Anne Zoller
Other/IR Contact Officer
Cindy McGee
Other
Andrea Braun
Other
Thomas Jung
Other
Bettina Stubinski
Director
Mats Blom
Non-Executive Independent Director
Oliver Kubli
Director
Alain Munoz
Non-Executive Independent Director
Berndt Modig
Non-Executive Independent Director
Armando Anido
Non-Executive Independent Director
Calvin Roberts
Non-Executive Independent Director
Wolfgang Arnold
No Data
  • All
  • Financials
  • Insiders
More
About EARS
Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

Webull offers kinds of Auris Medical Holding Ltd stock information, including NASDAQ:EARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EARS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EARS stock methods without spending real money on the virtual paper trading platform.